These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8238197)

  • 1. Genital and nongenital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse.
    Carbone JP; Brent RL
    Am J Obstet Gynecol; 1993 Nov; 169(5):1292-8. PubMed ID: 8238197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of gestational sex steroid exposure on limb development and endochondral ossification in the pregnant C57Bl/6J mouse: I. Medroxyprogesterone acetate.
    Carbone JP; Figurska K; Buck S; Brent RL
    Teratology; 1990 Aug; 42(2):121-30. PubMed ID: 2145652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
    Kumar D; Moore RM; Mercer BM; Mansour JM; Mesiano S; Schatz F; Lockwood CJ; Moore JJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the teratogenic potential of delalutin (17 alpha-hydroxyprogesterone caproate) in mice.
    Seegmiller RE; Nelson GW; Johnson CK
    Teratology; 1983 Oct; 28(2):201-8. PubMed ID: 6648824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins.
    Christian MS; Brent RL; Calda P
    J Matern Fetal Neonatal Med; 2007 Feb; 20(2):89-112. PubMed ID: 17437208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo.
    Northen AT; Norman GS; Anderson K; Moseley L; Divito M; Cotroneo M; Swain M; Bousleiman S; Johnson F; Dorman K; Milluzzi C; Tillinghast JA; Kerr M; Mallett G; Thom E; Pagliaro S; Anderson GD;
    Obstet Gynecol; 2007 Oct; 110(4):865-72. PubMed ID: 17906021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gestational exposure to hydroxyprogesterone caproate suppresses reproductive potential in male rats.
    Pushpalatha T; Reddy PR; Reddy PS
    Naturwissenschaften; 2005 Aug; 92(8):385-8. PubMed ID: 16049688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins.
    Attardi BJ; Zeleznik A; Simhan H; Chiao JP; Mattison DR; Caritis SN;
    Am J Obstet Gynecol; 2007 Dec; 197(6):599.e1-7. PubMed ID: 18060946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of progestational agents for preterm birth: lessons from a mouse model.
    Elovitz MA; Mrinalini C
    Am J Obstet Gynecol; 2006 Oct; 195(4):1004-10. PubMed ID: 17000233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974.
    Resseguie LJ; Hick JF; Bruen JA; Noller KL; O'Fallon WM; Kurland LT
    Fertil Steril; 1985 Apr; 43(4):514-9. PubMed ID: 3987922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impairment of male reproduction in adult rats exposed to hydroxyprogesterone caproate in utero.
    Pushpalatha T; Ramachandra Reddy P; Sreenivasula Reddy P
    Naturwissenschaften; 2004 May; 91(5):242-4. PubMed ID: 15146273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
    Mainiero AD; Rouse DJ; Lopes V; Hughes BL
    Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy.
    Waters TP; Schultz BAH; Mercer BM; Catalano PM
    Obstet Gynecol; 2009 Jul; 114(1):45-49. PubMed ID: 19546757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplacental transfer and metabolism of 17-alpha-hydroxyprogesterone caproate.
    Hemauer SJ; Yan R; Patrikeeva SL; Mattison DR; Hankins GD; Ahmed MS; Nanovskaya TN
    Am J Obstet Gynecol; 2008 Aug; 199(2):169.e1-5. PubMed ID: 18674659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dosing regimen for 17-hydroxyprogesterone caproate was suboptimal: lessons for future pharmacotherapy for pregnant women.
    Caritis SN; Dodeja P; Sharma S; Zhao W; Venkataramanan R
    Am J Obstet Gynecol; 2024 Apr; ():. PubMed ID: 38670444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial.
    Reijnders FJ; Thomas CM; Doesburg WH; Rolland R; Eskes TK
    Br J Obstet Gynaecol; 1988 May; 95(5):462-8. PubMed ID: 3135831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does 17-α-hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?
    Mulder EJ; Versteegh EM; Bloemenkamp KW; Lim AC; Mol BW; Bekedam DJ; Kwee A; Bruinse HW; Christiaens GC
    Ultrasound Obstet Gynecol; 2013 Sep; 42(3):329-34. PubMed ID: 23592400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta).
    Prahalada S; Tarantal AF; Harris GS; Ellsworth KP; Clarke AP; Skiles GL; MacKenzie KI; Kruk LF; Ablin DS; Cukierski MA; Peter CP; vanZwieten MJ; Hendrickx AG
    Teratology; 1997 Feb; 55(2):119-31. PubMed ID: 9143092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM; Lewis DF
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.